Gemigliptin

Gemigliptin is a pharmaceutical drug used in the treatment of Type 2 diabetes. It belongs to the class of antidiabetic drugs known as dipeptidyl peptidase-4 inhibitors or DPP-4 inhibitors.

Etymology

The name "Gemigliptin" is derived from the generic name of the drug. The suffix "-gliptin" is common among DPP-4 inhibitors, indicating its class.

Pharmacology

Gemigliptin works by inhibiting the enzyme dipeptidyl peptidase-4. This enzyme is involved in the breakdown of incretin hormones, which are responsible for increasing the amount of insulin released by the pancreas. By inhibiting this enzyme, Gemigliptin increases the levels of incretin hormones, leading to an increase in insulin release. This helps to lower blood glucose levels and control Type 2 diabetes.

Usage

Gemigliptin is used in the treatment of Type 2 diabetes. It is often used in combination with other antidiabetic drugs such as metformin or sulfonylureas to achieve better blood glucose control.

Side Effects

Common side effects of Gemigliptin include nausea, vomiting, diarrhea, and abdominal pain. In rare cases, it can cause pancreatitis or severe joint pain.

Related Terms

• Dipeptidyl peptidase-4 inhibitors
• Incretin
• Insulin
• Type 2 diabetes
• Metformin
• Sulfonylureas
• Pancreatitis

Gemigliptin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia